Allergan (AGN) announced that the FDA has approved its supplemental new drug application (sNDA) to update the labeling of combo antibiotic AVYCAZ (ceftazidime and avibactam) to include Phase 3 safety and efficacy data of AVYCAZ, in combination with the antibiotic metronidazole, for the treatment of complicated intra-abdominal infections (cIAI). The undated label also contains data on difficult-to-treat infections due pathogens resistant to ceftazidime and beta-lactam antibiotics.